Full-Time

Executive Director

Dmpk

Updated on 12/21/2024

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Healthcare

Compensation Overview

$262.3k - $379.8kAnnually

+ Annual Bonus + Equity-based Long-term Incentive Program

Senior, Expert

San Diego, CA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor's in chemistry, life sciences or closely related discipline and 17+ years of pharmaceutical/biotech experience, with extensive management experience. Experience in managing preclinical Contract Research Organizations. Experience managing preclinical scientists and preparation of INDs, CTDs, NDAs, and MAAs. Experience with silico modeling and simulation tools is beneficial OR
  • MS in Pharmacokinetics, Pharmaceutical Sciences, or closely related discipline and 15+ years of similar experience noted above OR
  • PhD in Pharmacokinetics, Pharmaceutical Sciences, or closely related discipline or PharmD and 12+ years of similar experience noted above
  • Demonstrated leadership of a Preclinical Pharmacokinetic function
  • Extensive experience in managing preclinical Contract Research Organizations
  • Excellent knowledge of preparation of INDs, CTAs, NDAs, and MAAs
  • Working knowledge of in silico modeling and simulation tools
  • Proactive, innovative, with good problem-solving skills
  • Knowledgeable of and current on regulatory guidance
  • Acts as a 'trusted advisor' across the company and may be recognized as an external expert
  • Provides strategy, vision and direction regarding issues that may have company-wide impact
  • Requires in-depth knowledge of the functional area, business strategies, and the company’s goals
  • Possesses industry-leading knowledge
  • Ability to work strategically in a cross functional team and matrix environment
  • Excellent written, presentation, and verbal communication skills
  • Exceptional leadership, coaching, employee development skills
  • Demonstrated ability to negotiate and influence others with or without authority at all levels of the organization
Responsibilities
  • Provides strategic, functional leadership and oversight to the Preclinical Pharmacokinetic function within Preclinical Development
  • Responsible for the development and enablement of departmental strategies to evaluate Preclinical Pharmacokinetics including ensuring continued expansion and/or updating of training, techniques and/or equipment
  • Leads and manages the conduct, interpretation and reporting of preclinical pharmacokinetic studies
  • Works with Research and Preclinical Development colleagues to establish optimal lead candidate characteristics, develop appropriate testing schemes, and design, conduct and report on preclinical studies intended to characterize potential drug candidates
  • Designs & conducts Preclinical Pharmacokinetic and Toxicokinetic/Pharmacokinetic/Pharmacodynamic studies in support of clinical development compounds
  • Oversees the preparation of Preclinical Pharmacokinetic sections of regulatory documents (IND, NDA, briefing books, Investigator Brochures, etc.)
  • Actively leads/participates in research-stage and development-stage program teams from both a strategic and tactical level
  • Prepares data summaries and presents results to peers, colleagues, the Management Committee and regulatory agencies
  • Prepares Standard Operating Procedures (SOPs) as needed to guide the Preclinical Pharmacokinetics activities
  • Performs other duties as assigned
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of CRENESSITY supports Neurocrine's innovative drug development strategy.
  • Partnership with PANTHERx Rare enhances patient access and support for CRENESSITY.
  • Neurocrine's focus on rare diseases aligns with industry trends towards first-in-class therapies.

What critics are saying

  • Increased competition in CAH treatments could impact Neurocrine's market share.
  • Reliance on PANTHERx Rare for distribution poses operational disruption risks.
  • Potential side effects of CRENESSITY could lead to regulatory scrutiny or reduced adoption.

What makes Neurocrine Biosciences unique

  • CRENESSITY is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
  • Neurocrine's CRENESSITY offers a novel approach with selective CRF1 receptor antagonism.
  • CRENESSITY is the first new CAH treatment in 70 years, marking a significant advancement.

Help us improve and share your feedback! Did you find this helpful?